Skip to main content
. Author manuscript; available in PMC: 2015 Jun 1.
Published in final edited form as: Mol Cancer Ther. 2014 May 13;13(6):1567–1577. doi: 10.1158/1535-7163.MCT-13-1023

Figure 5.

Figure 5

B-1239 stimulates ADCP by human and mouse macrophages. A, Cell counts of TXL2, US7, ICN13 or AML cells preincubated or not (control) with 25 μg/ml B-1239 followed by a 4-hour co-incubation with human macrophages. **p<0.01, ***p<0.001 compared to control. B, Percentage phagocytosis by human macrophages of US7 or TXL2 cells in an E:T ratio of 1:1 after 2 hrs in the presence of 20 μg/ml B-1239 or 20 μg/ml control human IgG. One of two experiments with independent macrophage isolates. C, Live cell counts of TXL2 and TXL2R in the presence of mouse SDM without further treatment (control) or with 100 nM nilotinib, 25 μg/ml B-1239, or both for 24 hrs. D, Live cell counts of the indicated Ph-positive pre-B ALLs treated as in (C). **p<0.01, for combination treatment compared to control. E, Live cell counts of US7 cells incubated with mouse BMDM or SDM in the presence or absence of 25 μg/ml B-1239.